The HIV-positive tuberculosis treatment success rate in the US is projected to be 72% in 2024, climbing to 73% by 2025 and maintaining this level through 2028. This marks a nominal increase from the estimated 71% success rate recorded in 2023. The year-on-year growth between 2024 and 2025 is approximately 1%, with the CAGR over the five-year forecast period indicating a stagnant development path with a slight increase.
Future trends to watch for include advancements in therapeutic technologies, changes in healthcare policies, increased funding for treatment programs, and new strategies to manage co-infections, potentially impacting treatment success rates positively. Monitoring these factors will be crucial for improving outcomes.
